Introduction
============

Mucinous adenocarcinoma (MAC) is an epithelial malignancy characterized by distinctive cells secreting abundant extracellular mucin.[@b1-cmar-9-573] SRCC is a rare subtype of MAC with ring-like cells in which the nucleus is displaced to the periphery by substantial intracytoplasmic mucin.[@b2-cmar-9-573] Verhulst et al[@b3-cmar-9-573] reported that colorectal SRCC is rare, and accounts for \<1% of all colorectal adenocarcinoma cases. Colorectal SRCC is associated with younger age, higher tumor grade, and poorer outcomes, compared with conventional adenocarcinoma.[@b4-cmar-9-573]--[@b9-cmar-9-573]

The World Health Organization defines SRCC as an adenocarcinoma with ≥50% SRCs in the tumor.[@b10-cmar-9-573] However, whether prognosis is associated with the SRC ratio in colorectal MAC-SRC remains unclear. Indeed, colorectal MAC comprising low SRC amounts (\<50%) has been seldom evaluated previously. Therefore, it is essential to assess the characteristics and prognostic factors of colorectal MAC-SRC in order to improve early diagnosis, treatment, and surveillance.

In the current study, we retrospectively analyzed the long-term outcomes of 95 patients with colorectal MAC-SRC in our institute, and evaluated the predictive value of the SRC ratio.

Patients and methods
====================

Patients
--------

A total of 95 consecutive colorectal MAC-SRC patients, from February 1987 to December 2015, were examined retrospectively. They had (a) colorectal MAC-SRC, confirmed pathologically by 2 pathologists independently through H&E staining in a retrospective review; (b) complete medical records with respect to demographic characteristics and laboratory findings; (c) no previous or concurrent malignancy; and (d) follow-up for more than 6 months after the definite diagnosis. Disease staging was performed according to the AJCC, 8th edition.[@b11-cmar-9-573] The present study was approved by the Ethics Committee of Fujian Cancer Hospital, Fuzhou, People's Republic of China (KT2017-010). Patient medical records and tumor specimens were analyzed retrospectively, with no individual patient identifiable information used. Therefore, individual consent was not required by the Ethics Committee.

Follow-up
---------

The patients were followed up clinically every 3 months for 1 year, every 6 months for the subsequent 2 years, and annually thereafter. Tumor progression was defined either pathologically or radiologically as local recurrence (recurrence close to the primary tumor bed or at the anastomotic stoma) and distant metastases (relapses in regions that could not be regarded as local recurrence).

Statistical analysis
--------------------

Research end points were PFS and OS. The Kaplan--Meier method was used to generate survival curves, with the log-rank test employed for comparison. Meanwhile, the cutoff point for the SRC ratio affecting survival was calculated using Cutoff Finder application.[@b12-cmar-9-573] A Cox regression model was used to evaluate predictive factors of PFS and OS. Two-sided *P*\<0.05 was considered statistically significant. PFS was defined as the time from pathological diagnosis to tumor progression or death. OS was determined as the time interval between pathological diagnosis and death due to any reason or last follow-up. Statistical analyses were conducted with SPSS version 22.0 (IBM Corporation, Armonk, NY, USA).

Results
=======

Patient characteristics
-----------------------

A total of 95 patients were enrolled in the present study. [Table 1](#t1-cmar-9-573){ref-type="table"} shows their baseline characteristics. Median age was 44 years (range 22--82), and the cohort included 47 (49.5%) males and 48 (50.5%) females. Among the 95 cases, 62.1% (59/95) had primary lesions in the rectum. Of the included patients, 52.1% (37/71) exhibited high pre-CEA levels (≥5.0 ng/mL), while 47.9% (34/71) had normal amounts (\<5.0 ng/mL). In addition, 8 (8.4%) and 9 (9.5%) patients underwent pre-CT and pre-RT, respectively. Forty-eight (50.5%) patients underwent post-CT, and 16 (16.8%) underwent post-RT.

Pathological features
---------------------

According to the Cutoff Finder software, 35% was considered the optimal cutoff point for the SRC ratio ([Figure 1](#f1-cmar-9-573){ref-type="fig"}). In all, 38 (40.0%) of 95 patients had \<35% SRCs, while 57 (60%) had values ≥35%. In this population, 81 patients underwent surgery; among them, 78 (96.3%) were diagnosed as stage T3 or T4, with 74 (91.4%) showing lymph node involvement and 27 (33.3%) presenting distant metastasis. Twelve (14.8%), 35 (43.2%), and 16 (19.8%) patients showed tumor nodules, LVI, and neural invasion, respectively.

Local control and survival outcomes
-----------------------------------

The median follow-up time was 29.7 months (range 0.8--165). In the current study, 84 of 95 (88.4%) patients experienced disease progression, of which 26/84 (40.0%) and 25/84 (29.8%) had locoregional relapse and distant metastasis, respectively. Locoregional relapse cases were of presacral (4/26, 15.4%), anastomotic (7/26, 26.9%), and pelvic (17/26, 65.4%) types. Common distant metastasis sites included the peritoneum (8%, 2/25), ovary (12.0%, 3/25), lung (16.0%, 4/25), bone (28.0%, 7/25), and lymph nodes (40.0%, 10/25). Median PFS was 22.9 months (range 0.7--164.9); 1-, 3-, and 5-year PFS rates for the whole population were 67.0% (95% CI 57.396--76.604%), 42.3% (95% CI 32.108--52.492%), and 25.6% (95% CI 16.192--35.008%), respectively. Meanwhile, 1-, 3-, and 5-year OS rates were 79.3% (95% CI 71.068--87.532%), 52.3% (95% CI 41.716--62.884%), and 42.5% (95% CI 31.720--53.280%), respectively.

Prognostic factors of PFS and OS
--------------------------------

[Table 2](#t2-cmar-9-573){ref-type="table"} summarizes the univariate and multivariate analyses of factors affecting PFS. Univariate analysis indicated that SRC ratio, bowel obstruction, M stage, and LVI were significantly associated with PFS (all *P*\<0.05). In addition, pre-RT was almost significantly correlated to PFS (*P*=0.053). Of these variables, SRC ratio (*P*=0.014, HR=1.917, 95% CI 1.140--3.225), pre-RT (*P*=0.015, HR=3.394, 95% CI 1.271--9.060), and M stage (*P*=0.044, HR=1.750, 95% CI 1.015--3.017) were independent prognostic factors of PFS. Univariate and multivariate analyses of OS are shown in [Table 3](#t3-cmar-9-573){ref-type="table"}. Univariate analysis revealed that SRC ratio, pre-CEA, pre-CT, and M stage were significantly associated with OS (all *P*\<0.05). Meanwhile, multivariate analysis showed that SRC ratio (*P*=0.032, HR=2.500, 95% CI 1.082--5.781), pre-CT (*P*=0.031, HR=3.755, 95% CI 1.127--12.517), and M stage (*P*=0.000, HR=3.219, 95% CI 1.676--6.181) were independent predictive factors of OS. [Figure 2](#f2-cmar-9-573){ref-type="fig"} displays the impact of the SRC ratio (\<35 vs ≥35%) on survival according to the Kaplan--Meier analysis.

Discussion
==========

This is one of the few studies focusing on the predictive value of SRC ratio in colorectal MAC-SRC patients with multiple prognostic factors. Our findings showed that SRC ratio ≥35% and distant metastasis indicated poor prognosis in colorectal MAC-SRC, while pre-CT and pre-RT improved survival.

Colorectal MAC has a dismal prognosis compared to classical adenocarcinoma.[@b1-cmar-9-573],[@b13-cmar-9-573] The reported 5-year OS rate is significantly lower for colorectal MAC than classical adenocarcinoma in the same site (17 vs 34%, *P*\<0.05).[@b1-cmar-9-573] In addition, Sung et al[@b9-cmar-9-573] and Tan et al[@b13-cmar-9-573] demonstrated that colorectal MAC patients with SRCs show poorer outcome than those without. Moreover, SRCC is considered an independent predictive factor of dismal prognosis.[@b14-cmar-9-573],[@b15-cmar-9-573] Reportedly, the 5-year OS rate of colorectal SRCC ranges from 0 to 31%,[@b5-cmar-9-573],[@b13-cmar-9-573],[@b15-cmar-9-573]--[@b17-cmar-9-573] obviously lower than that of the conventional colorectal MAC (range 48.0--69.0%).[@b9-cmar-9-573],[@b13-cmar-9-573],[@b17-cmar-9-573] In the current analysis, the 5-year OS rate in colorectal MAC-SRC patients was 42.5%, falling between MAC and SRCC rates. Interestingly, a previous study revealed that the morphological and molecular characteristics of colorectal MAC with low amounts of SRCs (\<50%) are similar to those of SRCC.[@b18-cmar-9-573] Therefore, we hypothesized that the SRC ratio is associated with the dismal prognosis of colorectal MAC-SRC. As shown above, 35% was the cutoff point of the SRC ratio. The above results showed that the 5-year PFS and OS rates in patients with SRC ratios \<35% were higher than those of individuals with ≥35% (PFS, 37.0 vs 14.7%, *P*=0.048; OS, 50.7 vs 33.2%, *P*=0.035, respectively). Importantly, the SRC ratio was an independent prognostic factor of PFS (*P*=0.014, HR=1.917, 95% CI 1.140--3.225) and OS (*P*=0.032, HR=2.500, 95% CI 1.082--5.781). In general, refining the impact of the SRC ratio on survival could help implement more aggressive treatments for patients with poor prognosis, and provides a basis for building an optimal prognostic system. Therefore, pathologists are advised to identify any SRC component and focus intensively on patients with colorectal MAC-SRC, especially those with low amounts of SRCs. Based on our findings, 35% might be an optimal cutoff point for predicting the outcome of colorectal MAC-SRC.

In agreement with previous colorectal SRCC data,[@b4-cmar-9-573],[@b5-cmar-9-573],[@b7-cmar-9-573]--[@b9-cmar-9-573] colorectal MAC-SRC patients were commonly diagnosed at an advanced stage in this study, with distant metastasis or lymph node metastasis. In a previous study examining 59 patients, 58 (98.3%) individuals had T3/T4 lesions, 52 (88.1%) showed lymph node metastasis, and 14 (23.7%) had distant metastasis.[@b5-cmar-9-573] In line with previous reports, almost all cases (96.3%) in the current study were diagnosed as stage T3 or T4, with 91.4% and 29.3% showing lymph node involvement and distant metastasis, respectively. Early diagnosis might be challenging because colorectal MAC-SRC is merely asymptomatic in the initial stage. However, SRCs are histologically more aggressive due to the absence of cell-to-cell adhesion, which leads to a high tendency of metastasis.[@b7-cmar-9-573],[@b9-cmar-9-573],[@b19-cmar-9-573] The reported incidence of peritoneal metastasis in colorectal SRCC is 38%, with a combined rate at other sites, including the liver, lung, bone, and brain, of only 18.5%.[@b4-cmar-9-573] Additionally, colorectal tumors with \<50% SRCs have a predisposition (75.0%) to metastasize to the peritoneum and ovaries.[@b19-cmar-9-573] Similarly, we observed that colorectal MAC-SRC metastasized predominantly to the peritoneum (40.7%) and ovaries (29.6%), and rarely to the liver, lung, and bone (18.5% combined). For the 38 patients with \<35% SRCs, the rate of peritoneal and ovarian metastasis was 18.4%, while 21.1% was obtained for the 57 patients with ≥35% SRCs. Hence, a high peritoneal and ovarian metastasis rate and a relatively low incidence of liver or lung metastasis may constitute a unique characteristic of colorectal MAC-SRC. This might be ascribed to poor prognosis since the patients cannot be treated by radical surgery to diffuse the peritoneal metastasis. In the current study, distant metastasis was an independent predictor of PFS (*P*=0.044, HR=1.750, 95% CI 1.015--3.017) and OS (*P*=0.000, HR=3.219, 95% CI 1.676--6.181), indicating the poor outcome of MAC-SRC.

Previous studies demonstrated that colorectal SRCC is more common in younger individuals (≤40-year-old) than non-SRC MAC.[@b4-cmar-9-573],[@b5-cmar-9-573],[@b7-cmar-9-573],[@b14-cmar-9-573] The reported mean age of colorectal SRCC patients is 48.1 years, while 57.4 years was found for colorectal MAC.[@b20-cmar-9-573] Young age (≤40-year-old) was shown to be an independent predictive factor of disease outcome in a previous study.[@b7-cmar-9-573] In this work, the median age of colorectal MAC-SRC patients was 44 years, corroborating previous reports. However, no significant association was found between age and PFS (*P*=0.871) or OS (*P*=0.959). This might be explained by the fact that all colorectal MAC-SRC patients were enrolled in this analysis, including those with reduced SRC amounts (\<50%).

Fu et al[@b14-cmar-9-573] and Inamura et al[@b15-cmar-9-573] reported that a female predominance is common (range 56--73.4%), with females having a poor outcome in colorectal SRCC (*P*\<0.001),[@b14-cmar-9-573] while males show prevalence in other studies (range 64.4--68.2%).[@b4-cmar-9-573],[@b5-cmar-9-573],[@b20-cmar-9-573] Meanwhile, others found no significant difference between males and females.[@b5-cmar-9-573],[@b17-cmar-9-573] In the current work, females and males had equal rates (49.5 vs 50.5%), with no significant association between gender and PFS (*P*=0.199) or OS (*P*=0.128), corroborating the findings of Wang et al[@b5-cmar-9-573] and Hugen et al.[@b17-cmar-9-573]

Studies also showed a right-side predominance (44.0%) in colorectal SRCC,[@b21-cmar-9-573] while others consider the colonic site an independent prognostic factor (*P*=0.012).[@b14-cmar-9-573] As shown above, all sites were involved in colorectal MAC-SRC, with rectal MAC-SRC being rather common (62.1%), in line with the literature.[@b4-cmar-9-573],[@b5-cmar-9-573] Moreover, Tawadros et al[@b7-cmar-9-573] demonstrated that rectal cancer morbidity in young patients (\<40) increases with an annual change of +3.6%; in addition, cancers in this population are more likely to exhibit the SRC component (about 3.6:1). In this study, young patients with rectal MAC-SRC (≤40-year-old) had a 5-year OS rate of 40.2%, while the median SRC ratio was 55%.

The 8th AJCC Cancer Staging recommends pre-CEA and LVI as prognostic and predictive factors of colorectal cancer.[@b11-cmar-9-573] Indeed, pre-CEA is considered an independent prognostic factor of colorectal cancer.[@b22-cmar-9-573] In the current cohort, pre-CEA had a significant impact on OS as assessed by univariate analysis (5-year OS, 38.4 vs 42.0%); however, it was not an independent predictive factor of MAC-SRC (*P*=0.100). Meanwhile, LVI is considered an independent prognostic factor of SRCC (HR=2.888, 95% CI 1.115--7.483).[@b5-cmar-9-573] In agreement, Barresi et al[@b23-cmar-9-573] showed that VI, assessed by IHC staining, is an independent prognostic factor of disease-free survival (*P*=0.02) and cancer-specific survival (*P*=0.001). In the current cohort, LVI had a significant impact on PFS (*P*=0.032) but was not an independent predictive factor of MAC-SRC (*P*=0.112). The pathological characteristics were assessed by H&E rather than IHC staining in this work, and we could not distinguish VI from LVI. Thus, IHC staining should be applied in further studies with larger sample sizes.

To the best of our knowledge, surgical resection is the gold standard treatment for resectable colorectal cancer. Nevertheless, SRCC cases display greater intolerability to surgery than non-SRCC ones, with recurrence or death within a short period of time post-surgery (24.5 vs 13.0%, *P*=0.001).[@b14-cmar-9-573] Here, we observed that pre-CT and pre-RT could improve survival in colorectal MAC-SRC, unlike post-CT and post-RT. In contrast, a large population-based study in the Netherlands observed longer survival in stage III SRCC patients treated with post-CT; however, a significant interaction between SRCC and chemotherapy was not observed (*P*=0.54).[@b17-cmar-9-573] In addition, neither pre-RT nor post-RT was found to affect survival in SRCC.[@b4-cmar-9-573] Due to its rarity, studies exploring the optimal treatment strategy for colorectal SRCC are scarce. However, because of the aggressive nature of SRC, it is necessary to gain insights into the potential treatment options to enhance survival in these patients.

Limitations
===========

This retrospective study had some limitations. First, it was a single-center clinical research that only enrolled 95 patients with colorectal MAC-SRC due to the rarity of the disease. Thus, multicenter studies are warranted for further exploring the disease. Secondly, 14 patients underwent no surgery and \>10% had missing T- and N-stage data in this retrospective analysis, which might result in selection bias. Thirdly, we provided only limited novel information about the morphological and molecular characteristics of SRCs, which necessitate additional studies.

Conclusion
==========

Overall, we assessed the long-term survival outcomes and identified the SRC ratio as an independent prognostic factor of colorectal MAC-SRC. Moreover, M stage might be negatively correlated with prognosis, while pre-CT and pre-RT could prolong survival independently. However, further studies are required to confirm these findings and explore the molecular mechanisms underlying the SRC components that affect survival.
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###### 

Patient characteristics

  Characteristics                          Data, n (%)
  ------------------- -------------------- -------------
  Gender                                   
                      Male                 47 (49.5)
  Female              48 (50.5)            
  Age                                      
                      Median (range)       44 (22--82)
  ≤40                 38 (40.0)            
  \>40                57 (60.0)            
  Location                                 
                      Ileocecal junction   7 (7.4)
  Right colon         12 (12.6)            
  Left colon          17 (17.9)            
  Rectum              59 (62.1)            
  SRC ratio                                
                      \<35                 38 (40.0)
  ≥35                 57 (60.0)            
  Pre-CEA (ng/mL)                          
                      \<5.0                34 (35.8)
  ≥5.0                37 (38.9)            
  Unknown             24 (25.3)            
  Bowel obstruction                        
                      Yes                  21 (22.1)
  No                  74 (77.9)            
  Pre-CT                                   
                      Yes                  8 (8.4)
  No                  87 (91.6)            
  Pre-RT                                   
                      Yes                  9 (9.5)
  No                  86 (90.5)            
  T stage                                  
                      1                    1 (11)
  2                   2 (2.1)              
  3                   43 (45.3)            
  4                   35 (36.8)            
  Unknown             14 (14.7)            
  N stage                                  
                      0                    7 (7.4)
  1                   16 (16.8)            
  2                   58 (61.1)            
  Unknown             14 (14.7)            
  M stage                                  
                      0                    65 (68.4)
  1                   27 (28.4)            
  Unknown             3 (3.2)              

**Abbreviations:** SRC, signet ring cell; pre-CEA, preoperative carcinoembryonic antigen; pre-CT, preoperative chemotherapy; pre-RT, preoperative radiotherapy.

###### 

Correlation between clinicopathological factors and progression-free survival

  Characteristics                                     Univariate   Multivariate                          
  --------------------------------------------------- ------------ -------------- ---------------------- -------
  Gender                                                                                                 
   Male/female                                        1.648        0.199                                 
  Age                                                                                                    
   ≤40/\>40                                           0.026        0.871                                 
  Location                                                                                               
   Ileocecal junction/right colon/left colon/rectum   4.949        0.176                                 
  SRC ratio                                                                                              
   \<35/≥35                                           3.915        0.048          1.917 (1.140--3.225)   0.014
  Pre-CEA (ng/mL)                                                                                        
   \<5.0/≥ 5.0                                        2.895        0.089                                 
  Bowel obstruction                                                                                      
   Yes/no                                             3.918        0.048          1.633 (0.892--2.991    0.112
  Pre-CT                                                                                                 
   Yes/no                                             2.003        0.157                                 
  Pre-RT                                                                                                 
   Yes/no                                             3.752        0.053          3.394 (1.271--9.060)   0.015
  T stage                                                                                                
   1/2/3/4                                            3.968        0.265                                 
  N stage                                                                                                
   0/1/2                                              4.733        0.094                                 
  M stage                                                                                                
   0/1                                                6.959        0.008          1.750 (1.015--3.017)   0.044
  Carcinoma nodules                                                                                      
   ±                                                  0.389        0.533                                 
  Lymphovascular invasion                                                                                
   ±                                                  4.584        0.032          1.662 (0.972--2.843)   0.063
  Neural invasion                                                                                        
   ±                                                  1.191        0.275                                 
  Post-CT                                                                                                
   Yes/no                                             0.663        0.416                                 
  Post-RT                                                                                                
   Yes/no                                             0.889        0.346                                 

**Abbreviations:** HR, hazard ratio; CI, confidence interval; SRC, signet ring cell; pre-CEA, preoperative carcinoembryonic antigen; pre-CT, preoperative chemotherapy; pre-RT, preoperative radiotherapy; post-CT, postoperative chemotherapy; post-RT, postoperative radiotherapy.

###### 

Correlation between clinicopathological factors and overall survival (OS).

  Characteristics                                     Univariate   Multivariate                           
  --------------------------------------------------- ------------ -------------- ----------------------- -------
  Gender                                                                                                  
   Male/female                                        2.317        0.128                                  
  Age                                                                                                     
   ≤40/\>40                                           0.003        0.959                                  
  Location                                                                                                
   Ileocecal junction/right colon/left colon/rectum   1.811        0.613                                  
  SRC ratio                                                                                               
   \<35/≥35                                           4.469        0.035          2.500 (1.082--5.781)    0.032
  Pre-CEA (ng/mL)                                                                                         
   \<5.0/≥5.0                                         8.423        0.004          1.808 (0.893--3.660)    0.100
  Bowel obstruction                                                                                       
   Yes/no                                             0.521        0.470                                  
  Pre-CT                                                                                                  
   Yes/no                                             4.505        0.034          3.755 (1.127--12.517)   0.031
  Pre-RT                                                                                                  
   Yes/no                                             2.964        0.085                                  
  T stage                                                                                                 
   1/2/3/4                                            2.993        0.393                                  
  N stage                                                                                                 
   0/1/2                                              4.969        0.083                                  
  M stage                                                                                                 
   0/1                                                13.171       0.000          3.219 (1.676--6.181)    0.000
  Carcinoma nodules                                                                                       
   ±                                                  3.137        0.077                                  
  Lymphovascular invasion                                                                                 
   ±                                                  2.108        0.147                                  
  Neural invasion                                                                                         
   ±                                                  0.698        0.403                                  
  Post-CT                                                                                                 
   Yes/no                                             0.207        0.649                                  
  Post-RT                                                                                                 
   Yes/no                                             1.397        0.237                                  

**Abbreviations:** HR, hazard ratio; CI, confidence interval; SRC, signet ring cell; pre-CEA, preoperative carcinoembryonic antigen; pre-CT, preoperative chemotherapy; pre-RT, preoperative radiotherapy; post-CT, postoperative chemotherapy; post-RT, postoperative radiotherapy.
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